First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.

被引：0
|
作者：
Wang, Junsheng
Li, Ning
Guo, Yanzhen
Cheng, Yufeng
Li, Baosheng
Luo, Suxia
机构：
[1] Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[4] Qilu Hosp Shandong Univ, Jinan, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [32] Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial
    Lan, Chun-Yan
    Zhao, Jing
    Yang, Fan
    Xiong, Ying
    Li, Rong
    Huang, Yu
    Wang, Jing
    Liu, Chang
    Bi, Xue-Han
    Jin, Hai-Hong
    Meng, Jin
    Zhao, Wei-Hong
    Zhang, Li
    Wang, Ya-Fei
    Zheng, Min
    Huang, Xin
    CELL REPORTS MEDICINE, 2022, 3 (07)
  • [33] Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08
    Wu, Xiaohua
    Chen, Xiaojun
    Luo, Xuezhen
    Wang, Ke
    Wang, Dong
    An, Ruifang
    Hou, Jianqing
    Yang, Ying
    Wang, Danbo
    Qu, Pengpeng
    Zhang, Bingzhong
    Duan, Wei
    Li, Xiumin
    Zang, Aimin
    Yu, Guohua
    Lou, Hanmei
    Yao, Desheng
    Wang, Shuzhen
    Yan, Dong
    Li, Liang
    Liu, Xiaowei
    Zhao, Weidong
    Chen, Zhengzheng
    Fei, Jing
    Li, Jundong
    Wang, Jing
    Wang, Zhilian
    Yao, Shuzhong
    Ning, Fangling
    Zhou, Huaijun
    Sun, Li
    Pan, Lingya
    Liu, Qing
    Yang, Haihua
    Wang, Li
    Zhang, Mingjun
    Chen, Xiaoxiang
    Yuan, Jianlin
    Zhang, Xinwen
    Zhang, Youzhong
    Liao, Qinping
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A6 - A6
  • [34] HEALTH OUTCOME IN PATIENTS WITH ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH FIRST-LINE SINTILIMAB PLUS CISPLATIN AND PACLITAXEL VERSUS CISPLATIN AND PACLITAXEL
    Sun, L.
    VALUE IN HEALTH, 2022, 25 (12) : S53 - S53
  • [35] Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Xu, Jianming
    Liu, Rongrui
    Zhang, Yanqiao
    Xu, Nong
    Fan, Qingxia
    Gao, Shegan
    Pan, Hongming
    Cai, Mingquan
    Yan, Dong
    Liang, Qianqian
    Wu, Qiong
    Guo, Baohong
    Qi, Yakun
    Xu, Ting
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
  • [37] Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Jia, Jun
    Gong, Jifang
    Li, Jie
    Li, Jian
    Li, Yan
    Zhang, Xiaotian
    Lu, Zhihao
    Zhou, Jun
    Zhang, Xiaodong
    CANCER SCIENCE, 2016, 107 (04) : 486 - 490
  • [38] A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
    Giuroiu, Iulia
    Ku, Geoffrey Yuyat
    Leichman, Lawrence P.
    Du, Kevin Lee
    Oh, Philmo
    Levinson, Benjamin A.
    Iqbal, Syma
    Thomas, Charles R.
    Wu, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
    Chang, J.
    Wang, H.
    Hu, Z.
    Wang, J.
    Wu, X.
    Zhao, X.
    Sun, S.
    Yu, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1292 - S1292
  • [40] Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis
    Zhang, Xiaodong
    Lu, Ming
    Gong, Jifang
    Gao, Jing
    Wang, Xicheng
    Zhang, Xiaotian
    Li, Jie
    Li, Yan
    Li, Jian
    Zhou, Jun
    Lu, Zhihao
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345